- Home
- XXII vs QLGN Comparison
XXII vs QLGN Comparison
Compare XXII & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XXII
- QLGN
- Stock Information
- Founded
- XXII 1998
- QLGN 1996
- Country
- XXII United States
- QLGN United States
- Employees
- XXII N/A
- QLGN N/A
- Industry
- XXII Medicinal Chemicals and Botanical Products
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- XXII Health Care
- QLGN Health Care
- Exchange
- XXII Nasdaq
- QLGN Nasdaq
- Market Cap
- XXII 2.8M
- QLGN 3.2M
- IPO Year
- XXII N/A
- QLGN N/A
- Fundamental
- Price
- XXII $5.10
- QLGN $4.07
- Analyst Decision
- XXII
- QLGN
- Analyst Count
- XXII 0
- QLGN 0
- Target Price
- XXII N/A
- QLGN N/A
- AVG Volume (30 Days)
- XXII 2.5M
- QLGN 20.7K
- Earning Date
- XXII 11-12-2024
- QLGN 11-14-2024
- Dividend Yield
- XXII N/A
- QLGN N/A
- EPS Growth
- XXII N/A
- QLGN N/A
- EPS
- XXII N/A
- QLGN N/A
- Revenue
- XXII $17,304,000.00
- QLGN N/A
- Revenue This Year
- XXII $56.94
- QLGN N/A
- Revenue Next Year
- XXII $2.98
- QLGN N/A
- P/E Ratio
- XXII N/A
- QLGN N/A
- Revenue Growth
- XXII N/A
- QLGN N/A
- 52 Week Low
- XXII $3.90
- QLGN $3.34
- 52 Week High
- XXII $581.85
- QLGN $29.45
- Technical
- Relative Strength Index (RSI)
- XXII 41.23
- QLGN 45.00
- Support Level
- XXII $4.80
- QLGN $3.95
- Resistance Level
- XXII $12.49
- QLGN $4.21
- Average True Range (ATR)
- XXII 2.00
- QLGN 0.27
- MACD
- XXII 0.36
- QLGN 0.00
- Stochastic Oscillator
- XXII 3.90
- QLGN 22.08
About XXII 22nd Century Group Inc.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.